Novartis AG is set to acquire Regulus Therapeutics Inc. in a deal potentially worth $1.7 billion, aiming to bring innovative treatments like farabursen to patients with ADPKD, pend...
Novartis AG is set to acquire Regulus Therapeutics in a deal worth up to $1.7B, aiming to advance the treatment for ADPKD through the development of farabursen, with the transactio...
Novartis AG announces a deal to acquire Regulus Therapeutics for up to $1.7 billion, including an initial $0.8 billion payment and a contingent value right for shareholders, aiming...
Novartis AG announces a strategic acquisition of Regulus Therapeutics Inc. for up to $1.7 billion, aiming to bring innovative treatments like farabursen to patients with ADPKD. The...
Novartis AG has entered into a groundbreaking agreement to acquire Regulus Therapeutics Inc. for up to $1.7 billion, including an initial $0.8 billion payment and potential future ...
Novartis AG is set to acquire Regulus Therapeutics Inc. in a deal worth up to $1.7 billion, including an initial payment of $0.8 billion and potential future payments based on regu...
Novartis AG has entered into an agreement to acquire Regulus Therapeutics Inc. in a deal worth up to $1.7 billion, aiming to bring innovative treatments to patients with ADPKD. The...
Novartis achieves a 40% EPS growth in Q1, reaching $1.83, showcasing strong performance and strategic growth in the pharmaceutical sector. More details to follow.
Novartis and Sanofi CEOs have urged the EU to increase drug prices, warning of the region's pharmaceutical sector decline. They propose measures like EU-wide list prices and spendi...
Novartis AG has agreed to acquire Anthos Therapeutics for up to $3.1 billion, with an upfront payment of $925 million and additional milestone-based payments. The deal, expected to...
Novartis AG reported a 15% increase in Q4 net sales to $13.15 billion, with a 7% rise in net income to $2.82 billion. The company's full-year net sales reached $50.32 billion, up 1...
